切换至 "中华医学电子期刊资源库"

中华诊断学电子杂志 ›› 2025, Vol. 13 ›› Issue (02) : 126 -132. doi: 10.3877/cma.j.issn.2095-655X.2025.02.010

综述

肠道菌群及其代谢产物与高血压的关系研究进展
吕豪1, 钱福凯2, 徐瑞1,()   
  1. 1. 250013 济南,山东第一医科大学附属中心医院心内科
    2. 257099 东营,胜利油田中心医院儿科
  • 收稿日期:2025-03-26 出版日期:2025-05-26
  • 通信作者: 徐瑞
  • 基金资助:
    山东省自然科学基金(ZR2023MH356)

Research progress on the relationship between gut microbiota and its metabolites and hypertension

Hao Lyu1, Fukai Qian2, Rui Xu1,()   

  1. 1. Department of Cardiology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China
    2. Department of Pediatrics, Shengli Oilfield Central Hospital,Dongying 257099, China
  • Received:2025-03-26 Published:2025-05-26
  • Corresponding author: Rui Xu
引用本文:

吕豪, 钱福凯, 徐瑞. 肠道菌群及其代谢产物与高血压的关系研究进展[J/OL]. 中华诊断学电子杂志, 2025, 13(02): 126-132.

Hao Lyu, Fukai Qian, Rui Xu. Research progress on the relationship between gut microbiota and its metabolites and hypertension[J/OL]. Chinese Journal of Diagnostics(Electronic Edition), 2025, 13(02): 126-132.

高血压是全球最常见的慢性病之一,其发病率持续上升,受环境和遗传等多因素影响。近年来研究表明,肠道菌群及其代谢产物在高血压的发生发展中发挥重要作用。笔者回顾了肠道菌群及其代谢产物与高血压之间的关联,重点探讨了益生菌补充、饮食调控、抗生素干预、粪菌移植等基于肠道菌群的高血压防治策略,并展望未来研究方向,以期为高血压的精准管理提供新思路。

Hypertension is one of the most prevalent chronic diseases worldwide, with a continuously increasing incidence influenced by multiple factors, including environmental and genetic factors. Recent studies have demonstrated that gut microbiota and its metabolites play a crucial role in the pathogenesis and progression of hypertension. This review summarizes the relationship between gut microbiota, its metabolites,and hypertension, with a particular focus on gut microbiota-based prevention and treatment strategies,including probiotic supplementation, dietary regulation, antibiotic intervention, and fecal microbiota transplantation. Furthermore, future research directions are discussed to provide new insights into the precise management of hypertension.

[1]
Zhang M,Shi Y,Zhou B,et al.Prevalence,awareness,treatment,and control of hypertension in China,2004-18: findings from six rounds of a national survey[J].BMJ,2023(380):e071952.DOI:10.1136/bmj-2022-071952.
[2]
McEvoy JW,McCarthy CP,Bruno RM,et al.2024 ESC Guidelines for the management of elevated blood pressure and hypertension[J].Eur Heart J,2024,45(38):3912-4018.DOI:10.1093/eurheartj/ehae178.
[3]
O′Donnell JA,Zheng T,Meric G,et al.The gut microbiome and hypertension[J].Nat Rev Nephrol,2023,19(3):153-167.DOI:10.1038/s41581-022-00654-0.
[4]
Ahmad AF,Dwivedi G,O′Gara F,et al.The gut microbiome and cardiovascular disease:current knowledge and clinical potential[J].Am J Physiol Heart Circ Physiol,2019,317(5):H923-H938.DOI:10.1152/ajpheart.00376.2019.
[5]
Chen L,He FJ,Dong Y,et al.Modest sodium reduction increases circulating short-chain fatty acids in untreated hypertensives:a randomized,double-blind,placebo-controlled trial[J].Hypertension,2020,76(1):73-79.DOI:10.1161/HYPERTENSIONAHA.120.14800.
[6]
Robles-Vera I,Toral M,de la Visitación N,et al.Probiotics prevent dysbiosis and the rise in blood pressure in genetic hypertension:role of short-chain fatty acids[J].Mol Nutr Food Res,2020,64(6):e1900616.DOI:10.1002/mnfr.201900616.
[7]
Pluznick JL,Protzko RJ,Gevorgyan H,et al.Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation[J].Proc Natl Acad Sci U S A,2013,110(11):4410-4415.DOI:10.1073/pnas.1215927110.
[8]
Natarajan N,Hori D,Flavahan S,et al.Microbial short chain fatty acid metabolites lower blood pressure via endothelial G proteincoupled receptor 41[J].Physiol Genomics,2016,48(11):826-834.DOI:10.1152/physiolgenomics.00089.2016.
[9]
Kaye DM,Shihata WA,Jama HA,et al.Deficiency of prebiotic fiber and insufficient signaling through gut metabolite-sensing receptors leads to cardiovascular disease[J].Circulation,2020,141(17):1393-1403.DOI:10.1161/CIRCULATIONAHA.119.043081.
[10]
Rose S,Bennuri SC,Davis JE,et al.Butyrate enhances mitochondrial function during oxidative stress in cell lines from boys with autism[J].Transl Psychiatry,2018,8(1):42.DOI:10.1038/s41398-017-0089-z.
[11]
Wu Y,Xu H,Tu X,et al.The role of short-chain fatty acids of gut microbiota origin in hypertension[J].Front Microbiol,2021(12):730809.DOI:10.3389/fmicb.2021.730809.
[12]
Poll BG,Xu J,Jun S,et al.Acetate,a short-chain fatty acid,acutely lowers heart rate and cardiac contractility along with blood pressure[J].J Pharmacol Exp Ther,2021,377(1):39-50.DOI:10.1124/jpet.120.000187.
[13]
Ratajczak W,Rył A,Mizerski A,et al.Immunomodulatory potential of gut microbiome-derived short-chain fatty acids (SCFAs)[J].Acta Biochim Pol,2019,66(1):1-12.DOI:10.18388/abp.2018_2648.
[14]
Liu YJ,Tang B,Wang FC,et al.Parthenolide ameliorates colon inflammation through regulating Treg/Th17 balance in a gut microbiotadependent manner[J].Theranostics,2020,10(12):5225-5241.DOI:10.7150/thno.43716.
[15]
Haghikia A,Jörg S,Duscha A,et al.Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine[J].Immunity,2015,43(4):817-829.DOI:10.1016/j.immuni.2015.09.007.
[16]
Bartolomaeus H,Balogh A,Yakoub M,et al.Short-chain fatty acid propionate protects from hypertensive cardiovascular damage[J].Circulation,2019,139(11):1407-1421.DOI:10.1161/CIRCULATIONAHA.118.036652.
[17]
Marques FZ,Nelson E,Chu PY,et al.High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice[J].Circulation,2017,135(10):964-977.DOI:10.1161/CIRCULATIONAHA.116.024545.
[18]
Hodgkinson K,El Abbar F,Dobranowski P,et al.Butyrate′s role in human health and the current progress towards its clinical application to treat gastrointestinal disease[J].Clin Nutr (Edinb Scotl),2023,42(2):61-75.DOI:10.1016/j.clnu.2022.10.024.
[19]
Guan Y,Chen K,Quan D,et al.The combination of scutellaria baicalensis georgi and sophora japonica l.ameliorate renal function by regulating gut microbiota in spontaneously hypertensive rats[J].Front Pharmacol,2020(11):575294.DOI:10.3389/fphar.2020.575294.
[20]
Kim S,Goel R,Kumar A,et al.Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure[J].Clin Sci (Lond),2018,132(6):701-718.DOI:10.1042/CS20180087.
[21]
Yang T, Rodriguez V, Malphurs WL, et al. Butyrate regulates inflammatory cytokine expression without affecting oxidative respiration in primary astrocytes from spontaneously hypertensive rats[J].Physiol Rep,2018,6(14):e13732.DOI:10.14814/phy2.13732.
[22]
Li Y,Zhou E,Yu Y,et al.Butyrate attenuates cold-induced hypertension via gut microbiota and activation of brown adipose tissue[J].Sci Total Environ,2024(943):173835.DOI:10.1016/j.scitotenv.2024.173835.
[23]
Yao L,Seaton SC,Ndousse-Fetter S,et al.A selective gut bacterial bile salt hydrolase alters host metabolism[J].Elife,2018(7):e37182.DOI:10.7554/eLife.37182.
[24]
Mistry RH,Verkade HJ,Tietge UJ.Reverse cholesterol transport is increased in germ-free mice-brief report[J].Arterioscler Thromb Vasc Biol,2017,37(3):419-422.DOI:10.1161/ATVBAHA.116.308306.
[25]
Jones BV,Begley M,Hill C,et al.Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome[J].Proc Natl Acad Sci U S A,2008,105(36):13580-13585.DOI:10.1073/pnas.0804437105.
[26]
Zhu Q,Zhu Y,Liu Y,et al.Moderation of gut microbiota and bile acid metabolism by chlorogenic acid improves high-fructoseinduced salt-sensitive hypertension in mice[J].Food Funct,2022,13(13):6987-6999.DOI:10.1039/d2fo00038e.
[27]
Ji CG,Xie XL,Yin J,et al.Bile acid receptor TGR5 overexpression is associated with decreased intestinal mucosal injury and epithelial cell proliferation in obstructive jaundice[J].Transl Res,2017(182):88-102.DOI:10.1016/j.trsl.2016.12.001.
[28]
Makishima M,Okamoto AY,Repa JJ,et al.Identification of a nuclear receptor for bile acids[J].Science,1999,284(5418):1362-1365.DOI:10.1126/science.284.5418.1362.
[29]
Gou X,Qin L,Wu D,et al.Research progress of takeda G proteincoupled receptor 5 in metabolic syndrome[J].Molecules,2023,28(15):5870.DOI:10.3390/molecules28155870.
[30]
Li C,Li J,Weng X,et al. Farnesoid X receptor agonist CDCA reduces blood pressure and regulates vascular tone in spontaneously hypertensive rats[J].J Am Soc Hypertens,2015,9(7):507-516.e7.DOI:10.1016/j.jash.2015.04.006.
[31]
Guo Y,Qiao R,Xie G,et al.Activation of TGR5 increases urine concentration by inducing AQP2 and AQP3 expression in renal medullary collecting ducts[J].Kidney Dis (Basel),2024,10(3):181-192.DOI:10.1159/000538107.
[32]
Shi H,Zhang B,Abo-Hamzy T,et al.Restructuring the gut microbiota by intermittent fasting lowers blood pressure[J].Circ Res,2021,128(9):1240-1254.DOI:10.1161/CIRCRESAHA.120.318155.
[33]
Yang K,Zhang P,Ding X,et al.Integrating bioinformatics and metabolomics to identify potential biomarkers of hypertensive nephropathy[J].Sci Rep,2025,15(1):7437.DOI:10.1038/s41598-025-89601-0.
[34]
Campbell C, McKenney PT, Konstantinovsky D, et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells[J].Nature,2020,581(7809):475-479.DOI:10.1038/s41586-020-2193-0.
[35]
Romano KA,Vivas EI,Amador-Noguez D,et al.Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide[J].mBio,2015,6(2):e02481.DOI:10.1128/mBio.02481-14.
[36]
Zeisel SH,Warrier M.Trimethylamine N-oxide,the microbiome,and heart and kidney disease[J].Annu Rev Nutr,2017(37):157-181.DOI:10.1146/annurev-nutr-071816-064732.
[37]
Liu Y,Dai M.Trimethylamine N-oxide generated by the gut microbiota is associated with vascular inflammation:new insights into atherosclerosis[J].Mediators Inflamm,2020,2020(1):4634172.DOI:10.1155/2020/4634172.
[38]
Ge X, Zheng L, Zhuang R, et al. The gut microbial metabolite trimethylamine n-oxide and hypertension risk:a systematic review and dose-response meta-analysis[J].Adv Nutr,2020,11(1):66-76.DOI:10.1093/advances/nmz064.
[39]
Jiang S,Shui Y,Cui Y,et al.Gut microbiota dependent trimethylamine N-oxide aggravates angiotensin II-induced hypertension[J].Redox Biol,2021(46):102115.DOI:10.1016/j.redox.2021.102115.
[40]
Caradonna E,Abate F,Schiano E,et al.Trimethylamine-N-oxide(TMAO) as a rising-star metabolite:implications for human health[J].Metabolites,2025,15(4):220.DOI:10.3390/metabo15040220.
[41]
Liu M, Han Q, Yang J. Trimethylamine-N-oxide (TMAO)increased aquaporin-2 expression in spontaneously hypertensive rats[J].Clin Exp Hypertens,2019,41(4):312-322.DOI:10.1080/10641963.2018.1481420.
[42]
Liu G,Cheng J,Zhang T,et al.Inhibition of microbiota-dependent trimethylamine N-oxide production ameliorates high salt diet-induced sympathetic excitation and hypertension in rats by attenuating central neuroinflammation and oxidative stress[J].Front Pharmacol,2022(13):856914.DOI:10.3389/fphar.2022.856914.
[43]
Ufnal M,Jazwiec R,Dadlez M,et al.Trimethylamine-N-oxide:a carnitine-derived metabolite that prolongs the hypertensive effect of angiotensin Ⅱ in rats[J].Can J Cardiol,2014,30(12):1700-1705.DOI:10.1016/j.cjca.2014.09.010.
[44]
Huc T,Drapala A,Gawrys M,et al.Chronic,low-dose TMAO treatment reduces diastolic dysfunction and heart fibrosis in hypertensive rats[J].Am J Physiol Heart Circ Physiol,2018,315(6):H1805-H1820.DOI:10.1152/ajpheart.00536.2018.
[45]
王世杰,陈松.肠源性三甲胺生成机制及其饮食调控[J].食品科学技术学报,2023,41(1):22-29.DOI:10.12301/spxb202200301.
[46]
Jang JW,Capaldi E,Smith T,et al.Trimethylamine N-oxide:a meta-organismal axis linking the gut and fibrosis[J].Mol Med,2024,30(1):128.DOI:10.1186/s10020-024-00895-8.
[47]
Xiao L,Dong JH,Teng X,et al.Hydrogen sulfide improves endothelial dysfunction in hypertension by activating peroxisome proliferator-activated receptor delta/endothelial nitric oxide synthase signaling[J].J Hypertens,2018,36(3):651-665.DOI:10.1097/HJH.0000000000001605.
[48]
Donertas Ayaz B,Oliveira AC,Malphurs WL,et al.Central administration of hydrogen sulfide donor NaHS reduces Iba1-positive cells in the PVN and attenuates rodent angiotensin II hypertension[J].Front Neurosci,2021(15):690919.DOI:10.3389/fnins.2021.690919.
[49]
Weber GJ, Pushpakumar S, Tyagi SC, et al. Homocysteine and hydrogen sulfide in epigenetic,metabolic and microbiota related renovascular hypertension[J].Pharmacol Res,2016,113(Pt A):300-312.DOI:10.1016/j.phrs.2016.09.002.
[50]
Tomasova L,Dobrowolski L,Jurkowska H,et al.Intracolonic hydrogen sulfide lowers blood pressure in rats[J].Nitric Oxide:Biol Chem,2016(60):50-58.DOI:10.1016/j.niox.2016.09.007.
[51]
Huc T, Jurkowska H, Wróbel M, et al. Colonic hydrogen sulfide produces portal hypertension and systemic hypotension in rats[J].Exp Biol Med (Maywood),2018,243(1):96-106.DOI:10.1177/1535370217741869.
[52]
Mu YF,Gao ZX,Mao ZH,et al.Perspectives on the involvement of the gut microbiota in salt-sensitive hypertension[J].Hypertens Res:Off J Jpn Soc Hypertens,2024,47(9):2351-2362.DOI:10.1038/s41440-024-01747-y.
[53]
Verhaar BJH,Prodan A,Nieuwdorp M,et al.Gut microbiota in hypertension and atherosclerosis:a review[J].Nutrients,2020,12(10):2982.DOI:10.3390/nu12102982.
[54]
Kaminsky LW,Al-Sadi R,Ma TY.IL-1β and the intestinal epithelial tight junction barrier[J].Front Immunol,2021(12):767456.DOI:10.3389/fimmu.2021.767456.
[55]
张兴宇,徐磊,卡德尔业·卡德尔,等.田蓟苷下调TLR4/Myd88/NF-κB信号通路抑制NLRP3炎症小体和炎症反应[J].药学学报,2024,59(7):2012-2019.DOI:10.16438/j.0513-4870.2024-0228.
[56]
Elijovich F,Laffer CL,Sahinoz M,et al.The gut microbiome,inflammation,and salt-sensitive hypertension[J].Curr Hypertens Rep,2020,22(10):79.DOI:10.1007/s11906-020-01091-9.
[57]
Grylls A,Seidler K,Neil J.Link between microbiota and hypertension:focus on LPS/TLR4 pathway in endothelial dysfunction and vascular inflammation,and therapeutic implication of probiotics[J].Biomed Pharmacother,2021(137):111334.DOI:10.1016/j.biopha.2021.111334.
[58]
Chai X,Liu L,Chen F.Oral nitrate-reducing bacteria as potential probiotics for blood pressure homeostasis[J].Front Cardiovasc Med,2024(11):1337281.DOI:10.3389/fcvm.2024.1337281.
[59]
Upadrasta A, Madempudi RS. Probiotics and blood pressure:current insights[J].Integr Blood Press Control,2016(9):33-42.DOI:10.2147/IBPC.S73246.
[60]
Wilck N, Matus MG, Kearney SM, et al. Salt-responsive gut commensal modulates TH17 axis and disease[J].Nature,2017,551(7682):585-589.DOI:10.1038/nature24628.
[61]
唐曼玉,王晚晴,强敬雯,等.益生菌与肠道菌群、免疫调节的相互作用与机制研究进展[J].食品工业科技,2022,43(16):486-493.DOI:10.13386/j.issn1002-00306.2022030025.
[62]
Yuan L,Li Y,Chen M,et al.Effects of probiotics on hypertension[J].Appl Microbiol Biotechnol,2023,107(4):1107-1117.DOI:10.1007/s00253-023-12369-8.
[63]
Hadi A, Pourmasoumi M, Kazemi M, et al. Efficacy of synbiotic interventions on blood pressure:a systematic review and metaanalysis of clinical trials[J].Crit Rev Food Sci Nutr,2022,62(20):5582-5591.DOI:10.1080/10408398.2021.1888278.
[64]
Wang W,Li Y,Han G,et al.Lactobacillus fermentum CECT5716 alleviates the inflammatory response in asthma by regulating TLR2/TLR4 expression[J].Front Nutr,2022(9):931427.DOI:10.3389/fnut.2022.931427.
[65]
孙鹏伟,皇甫卫忠.肠道菌群与高血压关系的研究进展[J].疑难病杂志,2024,23(6):751-755,768.DOI:10.3969/j.issn.1671-6450.2024.06.021.
[66]
Zhao TX,Zhang L,Zhou N,et al.Long-term use of probiotics for the management of office and ambulatory blood pressure:a systematic review and meta-analysis of randomized,controlled trials[J].Food Sci Nutr,2023,11(1):101-113.DOI:10.1002/fsn3.3069.
[67]
Rahman MdM,Islam F,-Or-Rashid MdH,et al.The gut microbiota(microbiome) in cardiovascular disease and its therapeutic regulation[J].Front Cell Infect Microbiol,2022(12):903570.DOI:10.3389/fcimb.2022.903570.
[68]
Aljuraiban GS,Gibson R,Chan DSM,et al.The role of diet in the prevention of hypertension and management of blood pressure:an umbrella review of meta-analyses of interventional and observational studies[J].Adv Nutr,2023,15(1):100123.DOI:10.1016/j.advnut.2023.09.011.
[69]
Reynolds AN,Akerman A,Kumar S,et al.Dietary fibre in hypertension and cardiovascular disease management:systematic review and meta-analyses[J].BMC Med,2022,20(1):139.DOI:10.1186/s12916-022-02328-x.
[70]
肖礼其,杨莉,崔赛仙,等.高盐诱导肠道菌群紊乱调节盐敏感性血压的机制研究[J].中国全科医学,2023,26(29):3704-3709.DOI:10.12114/j.issn.1007-9572.2022.0448.
[71]
Elijovich F,Kleyman TR,Laffer CL,et al.Immune mechanisms of dietary salt-induced hypertension and kidney disease:harry goldblatt award for early career investigators 2020[J].Hypertension,2021,78(2):252-260.DOI:10.1161/HYPERTENSIONAHA.121.16495.
[72]
Yan X,Jin J,Su X,et al.Intestinal flora modulates blood pressure by regulating the synthesis of intestinal-derived corticosterone in high salt-induced hypertension[J].Circ Res,2020,126(7):839-853.DOI:10.1161/CIRCRESAHA.119.316394.
[73]
Kim H,Lichtenstein AH,Coresh J,et al.Serum protein responses to dietary approaches to stop hypertension (DASH) and DASHsodium trials and associations with blood pressure changes[J].J Hypertens,2024,42(10):1823-1830.DOI:10.1097/HJH.0000000000003828.
[74]
Filippou CD,Tsioufis CP,Thomopoulos CG,et al.Dietary Approaches to Stop Hypertension (DASH) diet and blood pressure reduction in adults with and without hypertension:a systematic review and metaanalysis of randomized controlled trials[J].Adv Nutr,2020,11(5):1150-1160.DOI:10.1093/advances/nmaa041.
[75]
Barton W,Penney NC,Cronin O,et al.The microbiome of professional athletes differs from that of more sedentary subjects in composition and particularly at the functional metabolic level[J].Gut,2018,67(4):625-633.DOI:10.1136/gutjnl-2016-313627.
[76]
Clarke SF,Murphy EF,O'Sullivan O,et al.Exercise and associated dietary extremes impact on gut microbial diversity[J].Gut,2014,63(12):1913-1920.DOI:10.1136/gutjnl-2013-306541.
[77]
Yang T,Santisteban MM,Rodriguez V,et al.Gut dysbiosis is linked to hypertension[J].Hypertension,2015,65(6):1331-1340.DOI:10.1161/HYPERTENSIONAHA.115.05315.
[78]
Galla S,Chakraborty S,Cheng X,et al.Exposure to amoxicillin in early life is associated with changes in gut microbiota and reduction in blood pressure:findings from a study on rat dams and offspring[J].J Am Heart Assoc,2020,9(2):e014373.DOI:10.1161/JAHA.119.014373.
[79]
Galla S,Chakraborty S,Cheng X,et al.Disparate effects of antibiotics on hypertension[J].Physiol Genomics,2018,50(10):837-845.DOI:10.1152/physiolgenomics.00073.2018.
[80]
Yoo HH,Kim IS,Yoo DH,et al.Effects of orally administered antibiotics on the bioavailability of amlodipine:gut microbiota-mediated drug interaction[J].J Hypertens,2016,34(1):156-162.DOI:10.1097/HJH.0000000000000773.
[81]
Adnan S,Nelson JW,Ajami NJ,et al.Alterations in the gut microbiota can elicit hypertension in rats[J].Physiol Genomics,2017,49(2):96-104.DOI:10.1152/physiolgenomics.00081.2016.
[82]
Li J,Zhao F,Wang Y,et al.Gut microbiota dysbiosis contributes to the development of hypertension[J].Microbiome,2017,5(1):14.DOI:10.1186/s40168-016-0222-x.
[1] 朱晓璐, 孙希希, 柴佳园, 董泽洋, 赵梦瑶, 黄斌. 超声引导下医用无水乙醇硬化治疗卵巢子宫内膜异位囊肿疗效的影响因素分析[J/OL]. 中华医学超声杂志(电子版), 2025, 22(03): 215-223.
[2] 李文池, 沈拓. 光动力治疗在创面修复中应用的研究进展[J/OL]. 中华损伤与修复杂志(电子版), 2025, 20(03): 248-253.
[3] 孟洋, 刘婷, 杜锐, 崔颀, 尹传蓉, 刘燕, 宋佳. Er,Cr:YSGG激光技术治疗牙本质过敏症的新进展[J/OL]. 中华口腔医学研究杂志(电子版), 2025, 19(03): 210-216.
[4] 汪芷怡, 吴家惠, 沈世教, 蓝玺月, 马琳. 硼中子俘获疗法对口腔正常组织的辐射损伤研究现状[J/OL]. 中华口腔医学研究杂志(电子版), 2025, 19(03): 204-209.
[5] 欧阳凯彤, 李静远, 杜宇. 鼻咽癌放疗前的口腔准备[J/OL]. 中华口腔医学研究杂志(电子版), 2025, 19(03): 145-152.
[6] 何海霞, 白守民. 放疗在肌层浸润性膀胱癌保膀胱治疗中的应用现状及优化减毒策略[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(03): 288-295.
[7] 唐松林, 董宁, 叶艳芳, 刘乃云, 雷龙华, 黄怡健. 血压调控在治疗PCNL术后大出血中作用和机制的临床研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(03): 353-358.
[8] 谭小东, 代强, 张瑾, 黄鹏, 张鑫, 陈珊珊, 朱红学, 汪自力. 急诊行体外冲击波碎石术治疗输尿管结石临床疗效的影响因素分析[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(03): 359-364.
[9] 杨国荣, 叶晨曦, 王恒恩, 王杰, 胡强, 袁清, 宋涛. 前列腺三维重建影像在BPH 术前患者教育中的应用效果[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(03): 365-371.
[10] 廖俊豪, 周理林, 曾健文. 广东省医学会泌尿外科疑难病例多学科会诊(第25期)——膀胱癌根治术后盆腔复发[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(03): 390-394.
[11] 中国研究型医院学会肝胆胰外科专业委员会, 《中华消化外科杂志》编辑委员会. 肝门部胆管癌诊断和治疗指南(2025版)[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(03): 317-337.
[12] 刘立民, 张宗明, 赵月, 张翀, 刘卓, 齐晖. 医源性胆管损伤防治进展与现状[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(03): 346-353.
[13] 肿瘤康复专家共识编写专家组. 肿瘤康复专家共识(2025)[J/OL]. 中华临床医师杂志(电子版), 2025, 19(03): 165-179.
[14] 奚培培, 周加军. 慢性肾脏病相关性瘙痒症的研究进展[J/OL]. 中华临床医师杂志(电子版), 2025, 19(03): 216-220.
[15] 宋陈晨, 梁天赐, 赵悦, 张超贻, 王辉, 问婷芝, 戎彪学. X 型胶原α1 在恶性肿瘤中的研究进展[J/OL]. 中华临床医师杂志(电子版), 2025, 19(03): 221-228.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?